In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $7.98 down -0.13% from its previous closing price of $7.99. In other words, the price has decreased by -$0.13 from its previous closing price. On the day, 1.14 million shares were traded. OCUL stock price reached its highest trading level at $8.19 during the session, while it also had its lowest trading level at $7.91.
Ratios:
For a deeper understanding of Ocular Therapeutix Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.94 and its Current Ratio is at 13.01. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.21.
On June 20, 2024, TD Cowen Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $7 to $11.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 25 ’24 when Heier Jeffrey S. sold 2,948 shares for $9.01 per share. The transaction valued at 26,561 led to the insider holds 269,059 shares of the business.
Kaiser Peter sold 2,897 shares of OCUL for $26,102 on Nov 25 ’24. The Chief Development Officer now owns 213,087 shares after completing the transaction at $9.01 per share. On Nov 25 ’24, another insider, Nayak Sanjay, who serves as the Chief Strategy Officer of the company, sold 1,814 shares for $9.00 each. As a result, the insider received 16,326 and left with 174,380 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1254591616 and an Enterprise Value of 1161941120. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.42 while its Price-to-Book (P/B) ratio in mrq is 3.55. Its current Enterprise Value per Revenue stands at 19.018 whereas that against EBITDA is -10.492.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.21, which has changed by 0.7145922 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $3.92. The 50-Day Moving Average of the stock is -11.19%, while the 200-Day Moving Average is calculated to be -1.18%.
Shares Statistics:
For the past three months, OCUL has traded an average of 892.12K shares per day and 900500 over the past ten days. A total of 156.65M shares are outstanding, with a floating share count of 135.64M. Insiders hold about 13.72% of the company’s shares, while institutions hold 75.80% stake in the company. Shares short for OCUL as of 1730332800 were 12671361 with a Short Ratio of 12.04, compared to 1727654400 on 16194368. Therefore, it implies a Short% of Shares Outstanding of 12671361 and a Short% of Float of 8.1599995.
Earnings Estimates
The current rating of Ocular Therapeutix Inc (OCUL) reflects the combined expertise of 5.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.24 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.92 and -$1.23 for the fiscal current year, implying an average EPS of -$1.07. EPS for the following year is -$1.02, with 5.0 analysts recommending between -$0.96 and -$1.09.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $16.89M this quarter.It ranges from a high estimate of $17.78M to a low estimate of $15.7M. As of the current estimate, Ocular Therapeutix Inc’s year-ago sales were $14.8MFor the next quarter, 8 analysts are estimating revenue of $16.79M. There is a high estimate of $17.56M for the next quarter, whereas the lowest estimate is $16M.
A total of 9 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $66M, while the lowest revenue estimate was $62.3M, resulting in an average revenue estimate of $63.77M. In the same quarter a year ago, actual revenue was $58.44MBased on 9 analysts’ estimates, the company’s revenue will be $72.46M in the next fiscal year. The high estimate is $86.11M and the low estimate is $65.2M.
